Infuserve America Revenue and Competitors
Estimated Revenue & Valuation
- Infuserve America's estimated annual revenue is currently $5M per year.
- Infuserve America's estimated revenue per employee is $209,375
Employee Data
- Infuserve America has 24 Employees.
- Infuserve America grew their employee count by 14% last year.
Infuserve America's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Finance | Reveal Email/Phone |
2 | President Operations at Infuserve America | Reveal Email/Phone |
3 | Finance Associate/ Bookkeeper/ Accounts Receivable | Reveal Email/Phone |
4 | Farmacéutico | Reveal Email/Phone |
5 | President | Reveal Email/Phone |
6 | Staff Pharmacist | Reveal Email/Phone |
Infuserve America Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.5M | 132 | N/A | N/A | N/A |
#2 | $10.1M | 62 | 24% | N/A | N/A |
#3 | $282.6M | 1406 | N/A | N/A | N/A |
#4 | $13.9M | 69 | 44% | N/A | N/A |
#5 | $11.3M | 45 | -2% | N/A | N/A |
#6 | $11.5M | 46 | -2% | N/A | N/A |
#7 | $211.7M | 1072 | 4% | N/A | N/A |
#8 | $24.1M | 120 | 5% | N/A | N/A |
#9 | $7.8M | 39 | -2% | N/A | N/A |
#10 | $12.9M | 49 | -8% | N/A | N/A |
What Is Infuserve America?
Infuserve America is an Infusion and Compounding Pharmacy that specializes in the treatment of Lyme Disease. We are a unique collection of very experienced professionals that provide expert advice and quality products. Infuserve America takes pride in exceeding industry standards. We have state of the art facilities for medication compounding. Our products are tested for quality and sterility, and we comply with all applicable USP guidelines, and state and federal regulations.
keywords:N/AN/A
Total Funding
24
Number of Employees
$5M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 24 | N/A | N/A |
#2 | $2.5M | 24 | 0% | N/A |
#3 | $7.4M | 24 | -37% | N/A |
#4 | $2.4M | 24 | 4% | N/A |
#5 | $4.5M | 24 | 20% | N/A |